GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Amicus Therapeutics Inc (NAS:FOLD) » Definitions » Effective Interest Rate on Debt %

Amicus Therapeutics (Amicus Therapeutics) Effective Interest Rate on Debt % : 11.41% (As of Dec. 2023)


View and export this data going back to 2007. Start your Free Trial

What is Amicus Therapeutics Effective Interest Rate on Debt %?

Effective Interest Rate on Debt % is the usage rate that a borrower actually pays on a debt. It is calculated as the positive value of Interest Expense divided by its average total debt. Total debt equals to Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Amicus Therapeutics's annualized positive value of Interest Expense for the quarter that ended in Dec. 2023 was $51.3 Mil. Amicus Therapeutics's average total debt for the quarter that ended in Dec. 2023 was $449.7 Mil. Therefore, Amicus Therapeutics's annualized Effective Interest Rate on Debt % for the quarter that ended in Dec. 2023 was 11.41%.


Amicus Therapeutics Effective Interest Rate on Debt % Historical Data

The historical data trend for Amicus Therapeutics's Effective Interest Rate on Debt % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amicus Therapeutics Effective Interest Rate on Debt % Chart

Amicus Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Effective Interest Rate on Debt %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.10 6.88 7.36 8.32 11.18

Amicus Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Effective Interest Rate on Debt % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.83 10.48 11.05 11.46 11.41

Competitive Comparison of Amicus Therapeutics's Effective Interest Rate on Debt %

For the Biotechnology subindustry, Amicus Therapeutics's Effective Interest Rate on Debt %, along with its competitors' market caps and Effective Interest Rate on Debt % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Amicus Therapeutics's Effective Interest Rate on Debt % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Amicus Therapeutics's Effective Interest Rate on Debt % distribution charts can be found below:

* The bar in red indicates where Amicus Therapeutics's Effective Interest Rate on Debt % falls into.



Amicus Therapeutics Effective Interest Rate on Debt % Calculation

Amicus Therapeutics's annualized Effective Interest Rate on Debt % for the fiscal year that ended in Dec. 2023 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (A: Dec. 2022 )+Total Debt  (A: Dec. 2023 ))/ count )
=-1  *  -50.149/( (452.12+445.059)/ 2 )
=-1  *  -50.149/448.5895
=11.18 %

where

Total Debt  (A: Dec. 2022 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=443.568 + 8.552
=452.12

Total Debt  (A: Dec. 2023 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=436.735 + 8.324
=445.059

Amicus Therapeutics's annualized Effective Interest Rate on Debt % for the quarter that ended in Dec. 2023 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (Q: Sep. 2023 )+Total Debt  (Q: Dec. 2023 ))/ count )
=-1  *  -51.308/( (454.29+445.059)/ 2 )
=-1  *  -51.308/449.6745
=11.41 %

where

Total Debt  (Q: Sep. 2023 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=446.525 + 7.765
=454.29

Total Debt  (Q: Dec. 2023 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=436.735 + 8.324
=445.059

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Effective Interest Rate on Debt %, the Interest Expense of the last fiscal year and the average total debt over the fiscal year are used. In calculating the quarterly data, the Interest Expense data used here is four times the quarterly (Dec. 2023) interest expense data. Effective Interest Rate on Debt % is displayed in the 30-year financial page.


Amicus Therapeutics  (NAS:FOLD) Effective Interest Rate on Debt % Explanation

Effective Interest Rate on Debt % measures the usage rate that a borrower actually pays on a debt.


Amicus Therapeutics Effective Interest Rate on Debt % Related Terms

Thank you for viewing the detailed overview of Amicus Therapeutics's Effective Interest Rate on Debt % provided by GuruFocus.com. Please click on the following links to see related term pages.


Amicus Therapeutics (Amicus Therapeutics) Business Description

Industry
Traded in Other Exchanges
Address
3675 Market Street, Philadelphia, PA, USA, 19104
Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of advanced therapies to treat a range of devastating rare and orphan diseases.
Executives
John F Crowley director, officer: Executive Chairman C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
David Michael Clark officer: Chief People Officer 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Samantha Prout officer: Principal Accounting Officer C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Bradley L Campbell director, officer: President and CEO C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Ellen Rosenberg officer: General Counsel & Corp. Secy C/O AMICUS THERAPEUTICS, 1 CEDAR BROOK DRIVE, CRANBURY NJ 08560
Jeff Castelli officer: VP, Program Management 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Harford Simon N.r. officer: Chief Financial Officer AVON PRODUCTS, INC., 1345 AVENUE OF THE AMERICAS, NEW YORK NY 10105
Michael Raab director 1119 ST PAUL STREET, BALTIMORE MD 21202
Daphne Quimi officer: Chief Financial Officer C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Margaret G Mcglynn director C/O MERCK & CO INC, ONE MERCK DRIVE PO BOX 100, WHITEHOUSE STATION NJ 08889-0100
Burke W Whitman director 13455 NOEL ROAD # 2000, DALLAS TX 75240
Eiry Roberts director C/O NEUROCRINE BIOSCIENCES, INC., 12780 EL CAMINO REAL, SAN DIEO CA 92130
Hung Do officer: Sr Vice President Discovery C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Michael Aaron Kelly director C/O HOOKIPA PHARMA INC., 430 EAST 29TH ST., NEW YORK NY 10016
Jay Barth officer: Chief Medical Officer C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512